TrialFrontiers in immunology2025

Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Chen Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.